Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review

Andronis, Lazaros, Goranitis, Ilias, Bayliss, Sue and Duarte, Rui (2018) Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. PHARMACOECONOMICS, 36 (3). pp. 301-322.

Text Duarte_2017.pdf - Author Accepted Manuscript Download (1MB)

Abstract

<h4>Background</h4>Metastatic cancers occur when cancer cells break away from the primary tumour. One of the most common sites of metastasis is the bone, with several therapeutic options currently available for managing bone metastases. In a resource-constrained environment, policy makers and practitioners need to know which options are cost effective.<h4>Objective</h4>The aim of this systematic review was to review and appraise published economic evaluations on treatments for the management of bone metastases.<h4>Methods</h4>We searched eight bibliographic databases (MEDLINE, MEDLINE in Process, EMBASE, CSDR, DARE, HTA, EED and CPCI) for relevant economic evaluations published from each database's inception date until March 2017. Study selection, quality assessment and data extraction were carried out according to published guidelines.<h4>Results</h4>Twenty-four relevant economic analyses were identified. Seventeen of these studies focused on bone metastases resulting from a particular type of cancer, i.e. prostate (n = 8), breast (n = 7), lung (n = 1) or renal (n = 1), while seven report results for various primary tumours. Across types of cancer, evidence suggests that bisphosphonates result in lower morbidity and improved quality of life, for an additional cost, which is typically below conventional cost-effectiveness thresholds. While denosumab leads to health gains compared with zoledronic acid, it also results in substantial additional costs and is unlikely to represent value for money. The limited literature on the radiopharmaceutical strontium-89 (Sr89) and external beam radiotherapy (EBR) suggest that these treatments are cost effective compared with no treatment.<h4>Conclusions</h4>The reviewed evidence suggests that bisphosphonate treatments are cost-effective options for bone metastases, while denosumab is unlikely to represent value for money. Evidence on EBR and Sr89 is limited and less conclusive.

Item Type:	Article
Uncontrolled Keywords:	Humans, Bone Neoplasms, Radiotherapy, Cost-Benefit Analysis, Bone Density Conservation Agents
Depositing User:	Symplectic Admin
Date Deposited:	21 Nov 2017 14:12
Last Modified:	08 Feb 2024 05:42
DOI:	10.1007/s40273-017-0595-0
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3012641